TCG Labs-Soleil
Eric has an extensive background in the biotech and healthcare investment industry, with experience in asset acquisition, business development, and corporate development. He has a strong track record of working with various companies and organizations in the field, including founding and directing business development at Stingray Therapeutics. Eric currently serves as a Principal at TCG Labs-Soleil, where he focuses on therapeutics investments. With a Bachelor's degree in Biological Engineering from MIT and a Ph.D. in Bioengineering from Rice University, Eric brings a wealth of knowledge and experience to his role in the industry.
TCG Labs-Soleil
At TCG Labs-Soleil, we are establishing a pioneering venture-biotech model in collaboration with The Column Group. Our mission is to efficiently translate scientific insights into therapeutic solutions for patients facing serious diseases. Our approach integrates a dedicated venture fund (TCG Labs) with an evergreen R&D hub led by top-tier scientists (Soleil). This creates a powerful ecosystem forming and overseeing independent portfolio companies, each dedicated to single-asset biologic programs, guiding them from ideation to clinical proof of concept and positioning them for strategic partnerships and transformative medical advancements.